Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer's ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.

Enrollment in a 2025 Medicare plan opened for beneficiaries today. News outlets focus on an array of changes that could lead to "benefit disruption" that consumers should know about, in particular ...

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...

Shelhorn explained, “This is why early detection and diagnosis of Alzheimer's is more important than ever. According to a 2023 news release by Eisai, the manufacturers of LEQEMBI™( lecanemab ...

Dhivya Venkat, discusses the urgent need for integrating innovative diagnostics and therapies into the NHS in order to ...